Increased lipolysis by secretory phospholipase A2 group V of lipoproteins in diabetic dyslipidaemia

Journal of Internal Medicine

Volumn 264, Issue 2, 2008, Pages 155-165

  Pettersson, C ^a   Fogelstrand, L ^a   Rosengren, B ^b   Stahlman S ^a   Hurt Camejo, E ^a,b   Fagerberg, B ^a   Wiklund, O ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Atherosclerosis; LDL; Metabolic syndrome; Secretory phospholipase A 2 group V; Type 2 diabetes; VLDL

Indexed keywords

APOLIPOPROTEIN; FATTY ACID; LIPID; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN ISOLATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANALYSIS OF VARIANCE; CHOLESTEROL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS, NONESTERIFIED; FEMALE; GROUP V PHOSPHOLIPASES A2; HUMANS; LIPOLYSIS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; METABOLIC SYNDROME X; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 46949091379     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.01932.x     Document Type: Article

References (38)

1. Sartipy P, Hurt-Camejo E. Modification of plasma lipoproteins by group IIA phospholipase A(2): possible implications for atherogenesis. Trends Cardiovasc Med 1999 9 : 232 8.
2. Hernandez M, Fuentes L, Fernandez Aviles FJ, Crespo MS, Nieto ML. Secretory phospholipase A(2) elicits proinflammatory changes and upregulates the surface expression of fas ligand in monocytic cells: potential relevance for atherogenesis. Circ Res 2002 90 : 38 45.
3. Rinker KD, Kirkpatrick AP, Ting-Beall HP et al. Linoleic acid increases monocyte deformation and adhesion to endothelium. Atherosclerosis 2004 177 : 275 85.
4. Benitez S, Camacho M, Arcelus R et al. Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL. Atherosclerosis 2004 177 : 299 305.
5. Chang MY, Tsoi C, Wight TN, Chait A. Lysophosphatidylcholine regulates synthesis of biglycan and the proteoglycan form of macrophage colony stimulating factor. Arterioscler Thromb Vasc Biol 2003 23 : 809 15.
6. Ruiperez V, Casas J, Balboa MA, Balsinde J. Group V phospholipase A2-derived lysophosphatidylcholine mediates cyclooxygenase-2 induction in lipopolysaccharide-stimulated macrophages. J Immunol 2007 179 : 631 8.
7. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999 274 : 25913 20.
8. Wooton-Kee CR, Boyanovsky BB, Nasser MS, de Villiers WJ, Webb NR. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol 2004 24 : 762 7.
9. Hakala JK, Oorni K, Ala-Korpela M, Kovanen PT. Lipolytic modification of LDL by phospholipase A2 induces particle aggregation in the absence and fusion in the presence of heparin. Arterioscler Thromb Vasc Biol 1999 19 : 1276 83.
10. Rosengren B, Peilot H, Umaerus M et al. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler Thromb Vasc Biol 2006 26 : 1579 85.
11. Sartipy P, Bondjers G, Hurt-Camejo E. Phospholipase A2 type II binds to extracellular matrix biglycan: modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes. Arterioscler Thromb Vasc Biol 1998 18 : 1934 41.
12. Kugiyama K, Ota Y, Takazoe K et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999 100 : 1280 4.
13. Winkler K, Winkelmann BR, Scharnagl H et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen risk and cardiovascular health study. Circulation 2005 111 : 980 7.
14. Hartford M, Wiklund O, Hultén LM et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006 108 : 55 62.
15. Mallat Z, Benessiano J, Simon T et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007 27 : 1177 83.
16. Bostrom MA, Boyanovsky BB, Jordan CT et al. Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol 2007 27 : 600 6.
17. Gesquiere L, Cho W, Subbaiah PV. Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry 2002 41 : 4911 20.
18. Brohall G, Behre CJ, Hulthe J, Wikstrand J, Fagerberg B. Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care 2006 29 : 363 7.
19. Bingley PJ, Bonifacio E, Mueller PW. Diabetes antibody standardization program: first assay proficiency evaluation. Diabetes 2003 52 : 1128 36.
20. Dekker JM, Girman C, Rhodes T et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005 112 : 666 73.
21. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998 98 : 1487 94.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18 : 499 502.
23. Hulthe J, Wiklund O, Olsson G et al. Computerized measurement of LDL particle size in human serum. Reproducibility studies and evaluation of LDL particle size in relation to metabolic variables and the occurrence of atherosclerosis. Scand J Clin Lab Invest 1999 59 : 649 61.
24. Hallberg C, Haden M, Bergstrom M et al. Lipoprotein fractionation in deuterium oxide gradients: a procedure for evaluation of antioxidant binding and susceptibility to oxidation. J Lipid Res 1994 35 : 1 9.
25. Golay A, Swislocki AL, Chen YD, Reaven GM. Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism 1987 36 : 692 6.
26. Iwase M, Sonoki K, Sasaki N et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A(2) and effects of simvastatin treatment. Atheroscelrosis 2007 196 : 931 6.
27. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res 1988 29 : 1491 500.
28. Oorni K, Posio P, Ala-Korpela M, Jauhiainen M, Kovanen PT. Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler Thromb Vasc Biol 2005 25 : 1678 83.
29. Oorni K, Pentikainen MO, Ala-Korpela M, Kovanen PT. Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J Lipid Res 2000 41 : 1703 14.
30. Skipski VP. Lipid composition of lipoproteins in normal and diseased states. In : Nelson GJ, ed. Blood Lipids and Lipoproteins: Quantitation, Composition, and Metabolism. New York : Wiley Interscience, 1972 471 583.
31. Bagdade JD, Buchanan WE, Kuusi T, Taskinen MR. Persistent abnormalities in lipoprotein composition in noninsulin-dependent diabetes after intensive insulin therapy. Arterioscler Thromb Vasc Biol 1990 10 : 232 9.
32. Lane JT, Subbaiah PV, Otto ME, Bagdade JD. Lipoprotein composition and HDL particle size distribution in women with non-insulin-dependent diabetes mellitus and the effects of probucol treatment. J Lab Clin Med 1991 118 : 120 8.
33. Massey JB, Pownall HJ. Surface properties of native human plasma lipoproteins and lipoprotein models. Biophys J 1998 74 : 869 78.
34. Bengtsson G, Olivecrona T. Human C-apolipoproteins promote hydrolysis of dimyristoyl phosphatidylcholine by snake venom phospholipase A2. FEBS Lett 1982 140 : 135 8.
35. Winget JM, Pan YH, Bahnson BJ. The interfacial binding surface of phospholipase A2s. Biochim Biophys Acta 2006 1761 : 1260 9.
36. Adiels M, Boren J, Caslake MJ et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005 25 : 1697 703.
37. Hiukka A, Fruchart-Najib J, Leinonen E, Hilden H, Fruchart JC, Taskinen MR. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia 2005 48 : 1207 15.
38. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003 31 : 1066 9.